Over the past several years, Accelerate Diagnostics, together with our scientific collaborators, conducted numerous scientific studies supporting the exciting capabilities of our ID/AST System. Many of these studies resulted in posters presented at international conferences and peer-reviewed publications. We have conducted over 87,000 internal identification and susceptibility experiments across a panel of more than 20 of the most clinically prevalent species in sample types such as positive blood cultures and BALs. These studies demonstrated compelling performance versus reference and comparator methods, the results of which have been consistently duplicated by our clinical research partners. Below you will find links to some of these posters and publications.
These publications may include information from one or more organism/antimicrobial combinations that are research use only and not for use in diagnostic procedures.
Certain uses of devices included in these publications may not have been approved or cleared by the U.S. Food and Drug Administration or other regulatory bodies.
See product labeling for instructions for use, warnings, and limitations specific to each product and region.Okay, I understand. Show me the publications.
Randomized Trial Evaluating Clinical Impact of RAPid IDentification and Susceptibility Testing for Gram Negative Bacteremia (RAPIDS-GN)
Clinical Infectious Diseases
Banerjee R, Komarow L, Virk A, et al. (Antibacterial Resistance Leadership Group (ARLG))
Performance of the Accelerate Pheno system in a tertiary care hospital in Germany
Benjamin Berinson, Flaminia Olearo, Anna Both, et al. (University Medical Center Hamburg-Eppendorf)
Comparison of the Accelerate Pheno rapid diagnostic system with standard of care for diagnosing Gram-negative bloodstream infections: bacterial identification, antimicrobial sensitivity and turnaround time
Luke Blagdon Snell, Jasper Vink, Lyndsay Rowley, et al. (Guy's and St Thomas' NHS Foundation Trust, King's College London, St George's Hospital)
Evaluation of antimicrobial susceptibility testing assays for ceftazidime-avibactam and ceftolozane-tazobactam with Gram-negative bacteria directly from positive blood culture on the Accelerate Pheno system
Niels Oppermann, Anyangatia Ndobegang, Aaron Sikorski, et al. (Accelerate Diagnostics)
Phenotypic testing of ceftriaxone susceptibility on the Pheno system in characterised Enterobacterales
Amira Bhalodi, Nico Magnano, Romney Humphries (Accelerate Diagnostics)
Improving Outcomes and Antibiotic Stewardship for patients with bloodstream Infections (IOAS): a quasiexperimental multi-centre analysis of time to optimal therapy
Amira Bhalodi, Shawn Macvane, Margie Morgan, et al. (Cedars-Sinai Medical Center, UAMS - University of Arkansas for Medical Sciences, University of Iowa Hospitals & Clinics, Accelerate Diagnostics)
Using the Antibiotic Spectrum Index (ASI) score to assess antibiotic exposure for patients with Bloodstream Infections (BSI): an analysis of the Accelerate PhenoTest BC Kit (AXDX) IOAS study
Shawn Macvane, Amira Bhalodi, Margie Morgan, et al. (Cedars-Sinai Medical Center, UAMS - University of Arkansas for Medical Sciences, University of Iowa Hospitals & Clinics, Accelerate Diagnostics)
Turnaround time for pathogen identification and antimicrobial susceptibility testing of bronchoalveolar lavage specimens in U.S. acute care hospitals
Shawn Macvane, Niels Oppermann, Romney Humphries (Accelerate Diagnostics)
The effectiveness of two rapid identification technologies in Gram-negative bacteraemia without antimicrobial stewardship interventions
Lee Nguyen, Donna Chong, Jenee Vo, et al. (Loma Linda University)